Avoxred

Avoxred

azacitidine

Manufacturer:

Dr. Reddy's Lab

Distributor:

DKSH
Concise Prescribing Info
Contents
Azacitidine
Indications/Uses
Adult patients who are ineligible for haematopoietic stem cell transplantation w/ intermediate-2 & high-risk myelodysplastic syndrome, chronic myelomonocytic leukemia w/ 10-29% marrow blasts w/o myeloproliferative disorder, acute myeloid leukemia w/ 20-30% blasts & multi-lineage dysplasia.
Dosage/Direction for Use
75 mg/m2 SC inj daily for 7 days, followed by 21-day rest period (28-day treatment cycle) for min: 6 cycles.
Contraindications
Hypersensitivity. Advanced malignant hepatic tumours. Lactation.
Special Precautions
Discontinue use if necrotising fasciitis develops. History of CV or pulmonary disease; tumour lysis syndrome. Perform complete blood count & determine liver function tests, serum creatinine & bicarbonate prior to initiation & each treatment cycle. Assess cardiopulmonary prior to & during treatment. May affect ability to drive & use machines. Hepatic & renal impairment. Women of childbearing potential & men should use effective contraception during & up to 3 mth after treatment. Not to be used during 1st trimester of pregnancy.
Adverse Reactions
Febrile neutropenia, neutropenia; pneumonia; nausea. Adults w/ MDS, CMML & AML (20-30% marrow blasts): Anaemia; neutropenic sepsis; thrombocytopenia, leucopenia; hypersensitivity reactions & hemorrhagic events; GI events eg, vomiting; inj site reactions. Adults ≥65 yr w/ AML >30% marrow blasts: Pyrexia; GI events eg, constipation, diarrhea.
MIMS Class
Cytotoxic Chemotherapy
ATC Classification
L01BC07 - azacitidine ; Belongs to the class of antimetabolites, pyrimidine analogues. Used in the treatment of cancer.
Presentation/Packing
Form
Avoxred powd for inj 100 mg
Packing/Price
1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in